<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24499">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787824</url>
  </required_header>
  <id_info>
    <org_study_id>637/13.7</org_study_id>
    <nct_id>NCT02787824</nct_id>
  </id_info>
  <brief_title>Periodic Versus Continuous IV Iron Supplementation in HD Patients</brief_title>
  <official_title>Periodic Versus Continuous (at Every Session of Hemodialysis) iv Iron Supplementation in Chronic HD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papageorgiou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Papageorgiou General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the efficacy of two regimens of intravenous iron
      sucrose [continuous (in every hemodialysis session) versus intermittent (every 1-4 weeks)]
      on the response of rHuEPO in the maintenance phase of its administration in hemodialysis
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of serum hemoglobin level (g/dl)</measure>
    <time_frame>Month 0, 1, 2, 3, 4</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>continuous iv administration of iron sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermittent iv administration of iron sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose Supplement</intervention_name>
    <arm_group_label>continuous iv administration of iron sucrose</arm_group_label>
    <arm_group_label>intermittent iv administration of iron sucrose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Constant rHu-EPO and iron dose for at least 2 months before starting the study

          -  Hemoglobin â‰¥ 8,5g/dl and &lt;12,5 g/dl

          -  Ferritin &lt; 1000 mg/dl

          -  TSAT &lt; 50%

          -  CRP &lt; 5 mg/dl

        Exclusion Criteria:

          -  Malignant tumor disease

          -  Oral iron supplementation

          -  Active bleeding issues

          -  Surgical intervention within the last 8 weeks before study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EFSTATHIOS MITSOPOULOS, DIRECTOR</last_name>
    <email>mitsopouloss@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Papageorgiou General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efstathios Mitsopoulos, MD</last_name>
      <phone>0030-2310-693309</phone>
      <email>mitsopouloss@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 26, 2016</lastchanged_date>
  <firstreceived_date>May 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Papageorgiou General Hospital</investigator_affiliation>
    <investigator_full_name>Efstathios Mitsopoulos</investigator_full_name>
    <investigator_title>Director of Nephrology Dept</investigator_title>
  </responsible_party>
  <keyword>iron deficiency</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
